Xencor's stock drops 65%, hitting all-time lows. Focus shifts to autoimmune research, but no near-term catalysts. Read why ...

Conference call with management will be held on April 16 at 2 pm hosted by JPMorgan. Webcast LinkStay Ahead of the Market: Discover ...

Xencor (XNCR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. PASADENA ...

In a report released today, Peter Lawson from Barclays maintained a Sell rating on Xencor (XNCR – Research Report), with a price target of ...

Shares of Xencor, Inc. (NASDAQ:XNCR – Get Free Report) have been given a consensus rating of “Buy” by the eight research firms that are presently covering the firm, Marketbeat Ratings reports.

Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The firm had revenue of $52.79 million for the quarter, compared to analysts’ expectations of $17.14 million.

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases ...

Xencor, Inc., the US Court of Appeals for the Federal Circuit confirmed that the limiting preamble of a Jepson claim must be supported ...